Scisparc and clearmind collaboration continues to increase its patent portfolio in the field of movement abnormalities in the u.s.

Tel aviv, israel, aug. 01, 2023 (globe newswire) -- the new u.s. patent application is for the use of the psychedelic molecule 3-mmc and scisparc's palmitoylethanolamide to treat dyskinesia and dystonia known to occur in several rapid, non-rhythmic, abnormal movements disorders including tourette syndrome and parkinson's disease.
SPRC Ratings Summary
SPRC Quant Ranking